Arikayce™ 560 mg

Phase 2

Insmed Incorporated (INSM)

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

37 competitors in Cystic Fibrosis

VRTXTEZ/IVA

Phase 3

VRTXTezacaftor/Ivacaftor

VRTXVX-661 plus ivacaftor combination

Phase 3

View Full Landscape

Drug Information

Target Indication

Cystic Fibrosis

Clinical Trial

NCT00558844

Last updated: 12/4/2025

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

INSM

Insmed Incorporated

Pharmaceutical Preparations•North America•NASDAQ

Related Pipeline

Liposomal amikacin for inhalation (Arikayce™) using the PARI Investigational eFlow® Nebulizer.Phase 3

Pseudomonas Aeruginosa Infection

LAI 590 mgPhase 3

NTM Lung Infection Due to MAC

Liposomal amikacin for inhalationPhase 3

Cystic Fibrosis

Brensocatib 25 mgPhase 3

Non-Cystic Fibrosis Bronchiectasis

Treprostinil Palmitil Inhalation PowderPhase 3

Pulmonary Hypertension

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts